CD28/B7 Interactions Are Required for Sustaining the Graft-Versus-Leukemia Effect of Delayed Post-Bone Marrow Transplantation Splenocyte Infusion in Murine Recipients of Myeloid or Lymphoid Leukemia Cells

Journal of Immunology

Volumn 159, Issue 7, 1997, Pages 3460-3473

  Blazar, Bruce R ^a   Taylor, Patricia A ^a   Boyer, Michael W ^a,c   Panoskaltsis Mortari, Angela ^a   Allison, James P ^b   Vallera, Daniel A ^a  

^a UNIV OF MINNESOTA HOSP AND CLINIC   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B7 ANTIGEN; CD28 ANTIGEN; CD86 ANTIGEN; CD86 PROTEIN, MOUSE; LEUKOCYTE ANTIGEN; MEMBRANE PROTEIN;

ACUTE GRANULOCYTIC LEUKEMIA; ADOPTIVE TRANSFER; ANIMAL; ARTICLE; BIOSYNTHESIS; BONE MARROW TRANSPLANTATION; C57BL MOUSE; CANCER TRANSPLANTATION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL CULTURE; CYTOLOGY; GRAFT VERSUS HOST REACTION; IMMUNOLOGY; LYMPHOCYTE TRANSFUSION; METABOLISM; MORTALITY; MOUSE; SPLEEN; T CELL LEUKEMIA; TRANSPLANTATION;

ADOPTIVE TRANSFER; ANIMALS; ANTIGENS, CD; ANTIGENS, CD28; ANTIGENS, CD80; ANTIGENS, CD86; BONE MARROW TRANSPLANTATION; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; GRAFT VS HOST REACTION; LEUKEMIA, MYELOCYTIC, ACUTE; LEUKEMIA, T-CELL, ACUTE; LYMPHOCYTE TRANSFUSION; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED C57BL; NEOPLASM TRANSPLANTATION; SPLEEN; TUMOR CELLS, CULTURED;

EID: 0031252580     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (61)

1. Long, G. D., and K. G. Blume. 1994. Allogeneic bone marrow transplantation for acute myeloid leukemia. In Bone Marrow Transplantation. S. J. Forman, K. G. Blume, and E. D. Thomas, eds. Blackwell Scientific Publishers, Boston, pp. 607-617.
2. Clift, R. A , C. D. Buckner, F. R. Appelbaum, G. Schoch, F. B. Petersen, W. I. Bensinger, J. Sanders, K. Sullivan, R. Storb, J. Singer, J. A. Hansen, and E. D. Thomas. 1992. Allogeneic marrow transplantation during untreated first relapse of acute myeloid leukemia. J. Clin. Oncol. 10:1723.
3. Weisdorf, D. J., M. E. Nesbit, N. K. Ramsay, W. G. Woods, A. I. Goldman, T. H. Kim, D. D. Hurd, P. B. McGlave, and J. H. Kersey. 1987. Allogeneic bone marrow transplantation for acute lymphoblastic leukemia in remission: prolonged survival associated with acute graft-versus-host disease. J. Clin. Oncol. 5:1348.
4. Gale, R. P., and R. E. Champlin. 1984. How does bone-marrow transplantation cure leukaemia? Lancet 2:28.
5. Fefer, A., K. M. Sullivan, P. Weiden, C. D. Buckner, G. Schoch, R. Storb, and E. D. Thomas. 1987. Graft versus leukemia effect in man: the relapse rate of acute leukemia is lower after allogeneic than after syngeneic marrow transplantation. Prog. Clin. Biol. Res. 244:401.
6. Sullivan, K., P. Weiden, R. Storb, R. Witherspoon, A. Fefer, L. Fisher, C. Buckner, C. Anasetti, F. R. Appelbaum, C. Badger, P. Beatty, W. Bensinger. 1989. Influence of acute and chronic graft-versus-host disease on relapse and survival after bone marrow transplantation from HLA-siblings as treatment of acute and chronic leukemia. Blood 73:1720.
7. Horowitz, M. M., R. P. Gale, P. M. Sondel, J. M. Goldman, J. Kersey, H.-J. Kolb, A. A. Rimm, O. Ringden, C. Rozman, B. Speck, R. L. Truitt, F. E. Zwaan, and M. Bortin. 1990. Graft-versus-leukemia reactions after bone marrow transplantation. Blood 75:555.
8. Kersey, J. H., D. Weisdorf, M. E. Nesbil, T. W. LeBien, W. G. Woods, P. B. McGlave, T. Kim, D. A. Vallera, A. I. Goldman, B. Bostrom, D. Hurd, and N. K. C. Ramsay. 1987. Comparison of autologous and allogeneic bone marrow transplantation for treatment of high-risk refractory acute lymphoblastic leukemia. N. Engl. J. Med. 317:461.
9. Slavin, S., R. Or. E. Naparstek, A. Eckerstein, and L. Weiss. 1988. Cellular mediated immunotherapy of leukemia in conjunction with autologous and allogeneic bone marrow transplantation in experimental animals and man. Blood 72(Suppl. 1):407a.
10. Kolb, H. J., J. Mittermuller, C. Clemm, E. Holler, G. Ledederose, G. Brehm, M. Heim, and W. Wilmanns. 1990. Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood 76:2462.
11. Giralt, S. A., and R. E. Champlin. 1994. Leukemia relapse after allogeneic bone marrow transplantation: a review. Blood 84:3603.
12. Kolb, H.-J., A. Schattenberg, J. M. Goldman, B. Hertenstein, N. Jacobsen, W. Arcese, P. Ljungman, A. Ferrant, L. Verdonck, D. Niederwieser, F. van Rhee, J. Mittermueller, et al. 1995. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood 86:2041.
13. Collins, R. H., O Shpilberg, W. R. Drobyski, D. L. Porter, S. Giralt, R. Champlin, S. A. Goodman, S. N. Wolff, W. Hu, C. Verfaillie, A. List, W. Dalton, N. Ognoskie, A. Chetrit, J. H. Antin, and J. Nemunaitis. 1997. Donor leukocyte infusion in 140 patients wilh relapsed malignancy after allogeneic bone marrow transplantation. J. Clin. Oncol. 15:433.
14. Sullivan, K., R. Storb, C. Buckner, A. Fefer, L. Fisher, P. Weiden, R. Witherspoon, F. R. Appelbaum, M. Banaji, J. Hansen, P. Martin, J. E. Sanders, et al. 1990. Graft-versus-hosl disease as adoptive immunotherapy in patients with advanced hematologic neoplasms. N. Engl. J. Med. 320:828.
15. Mackinnon, S., E. B. Papadopoulos, M. H. Carabasi, L. Reich, N. H. Collins, F. Boulad, H. Castro-Malaspina, B. H. Childs, A. P. Gillio, N. A. Kernan, T. N. Small, J. W. Young, et al. 1995. Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukemia after bone marrow transplantation: separation of graft-versus-leukemia responses from graft-versus-host. Blood 86:1261.
16. Papadopoulos, E. B., M. Ladanyi, D. Emanuel, S. Mackinnon, F. Boulad, M. H. Carabasi, H. Castro-Malaspina, B. H. Childs, A. P. Gillio, T. N. Small, J. W. Young, N. A. Kernan, and R. J. O'Reilly. 1994. Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation. M Engl. J. Med. 330:1185.
17. Mackinnon, S., E. B. Papadopoulos, M. H. Carabasi, L. Reich, N. H. Collins, and R. J. O'Reilly. 1995. Adoptive immunotherapy using donor leukocytes following bone marrow transplantation for chronic myeloid leukemia: is T cell dose important in determining biological response. Bone Marrow Transplant. 15:591.
18. Hessner, M. J., D. J. Endean, J. T. Casper, M. M. Horowitz, C. A. Keever-Taylor, M. Roth, N. Flomenberg, and W. Drobyski. 1995. Use of unrelated marrow grafts compensates for reduced graft-versus-leukemia reactivity after T-cell-depleted allogeneic marrow transplantation for chronic myelogenous leukemia. Blood 86: 3987.
19. Giralt, S., J. Hester, Y. Huh, C. Hirsch-Ginsberg. G. Rondon, D. Seong, M. Lee, J. Gajewski, K. V. Besien, I. Khouri, R. Mehra, D. Przepiorka, et al. 1995. CD8-depleted donor lymphocyte infusion as treated for relapse chronic myelogenous leukemia after allogeneic marrow transplantation. Blood 86:4317.
20. Cardoso, A. A., J. L. Schultze, V. A. Boussiotis, G. J. Freeman, M. J Seamon, S. Laszlo, A. Billet, S. E. Sallan, J. G. Gribben, and L. M. Nadler. 1996. Pre-B acute lymphoblastic leukemia cells may induce T-cell anergy to alloantigen. Blood 88:41.
21. Chen, L., S. Ashe, W. A. Brady, I. Hellstrom, K. E. Hellstrom, J. A. Ledbetter, P. McGowan, and P. S. Linsley. 1992. Costimulation of antitumor immunity by the B7 counter-receptor for the T lymphocyte molecules CD28 and CTLA-4. Cell 71:1093.
22. Townsend, S. E., and J. P. Allison. 1993. Tumor rejection after direct costimulation of CD8+ T cells by B7-transfected melanoma cells. Science 259:368.
23. Baskar, S., S. Ostrand-Rosenberg, N. Nabavi, L. M. Nadler, G. J. Freeman, and L. H. Glimcher. 1993. Constitutive expression of B7 restores immunogenicity of tumor cells expressing truncated major histocompatibility complex class II molecules Proc. Natl. Acad. Sci. USA 90:5687.
24. Hellstrom, K. E., I. Hellstrom, and L. Chen. 1995. Can co-stimulated tumor immunity be therapeutically efficacious? Immunnl. Rev. 145:123.
25. Chen, L., P. McGowan, S. Ashe, J. Johnston, Y. Li, I. Hellstrom, and K. E. Hellstrom. 1994. Tumor immunogenicity determines the effect of B7 costimulation on T cell-mediated tumor immunity. J. Exp. Med. 179:523.
26. Chen, L., P. McGowan, S. Ashe, J. V. Johnston, I. Hellstrom and K. E. Hellstrom. 1994. B7-1/CD80-transduced tumor cells elicit better systemic immunity than wild-type tumor cells admixed with Corynebacterium parvum. Cancer Res. 54: 5420.
27. + cytolytic T lymphocytes. J. Exp. Med. 183:791.
28. Matulonis, U. A., C. Dosiou, C. Lamont, G. J. Freeman, P. Mauch, L. M. Nadler, and J. D. Griffin. 1995. Role of B7-1 in mediating an immune response to myeloid leukemia cells. Blood 85:2507.
29. Matulonis, U., C. Dosiou, G. Freeman, C. Lamont, P. Mauch, L. M. Nadler, and J. D. Griffin. 1996. B7-1 is superior to B7-2 costimulation in the induction and maintenance of T cell-mediated antileukemia immunity: further evidence that B7-1 and B7-2 are functionally distinct. J. Immunol. 156:1126.
30. Dunussi-Joannopoulos, K., H. J. Weinstein, P. W. Nickerson, T. B. Strom, S. J. Burakoff, J. M. Croop, and R. J. Arceci. 1996. Irradiated B7-1 transduced primary acute myelogenous leukemia (AML) cells can be used as therapeutic vaccines in murine AML. Blood 87:2938.
31. Huang, A. Y., A. T. Brace, D. M. Pardoll, and H. I. Levitsky. 1996. Does B7-1 expression confer antigen-presenting cell capacity to tumors in vivo? J. Exp. Med 183:769.
32. Blazar, B. R., P. A. Taylor, P. S. Linsley, and D. A. Vallera. 1994. In vivo blockade of CD28/CTLA4:B7/BB1 interaction with CTLA4-Ig reduces lethal murine graft-versus-host disease across the major histocompatibility complex (MHC) barrier in mice. Blood 83:3815.
33. + T cells. J. Immunol. 157:3250.
34. Johnson, B. D., W. R. Drobyski, and R. L. Train. 1993. Delayed infusion of normal donor cells after MHC-matched bone marrow transplantation provides an antileukemia reaction without graft-versus-host disease. Bone Marrow Transplant. 11:329.
35. Johnson, B. D., and R. L. Truitt. 1995. Delayed infusion of immunocompetent donor cells after bone marrow transplantation breaks graft-host tolerance and allows for persistent antileukemic reactivity without severe graft-versus-host disease. Blood 85:3302.
36. Johnson, B. D., C. McCade, C. A. Hanke, and R. L. Truitt. 1995. Use of anti-CD3∈F(ab′)2 fragments in vivo to modulate graft-versus-host disease without loss of graft-versus-leukemia reactivity after MHC matched bone marrow transplantation. J. Immunol. 154:5542.
37. + T cell line with potent in vivo graft-versus-leukemia properties. Blood. 89:3477.
38. Townsend, S. E., F. W. Su, J. M Atherton, and J. P. Allison. 1994. Specificity and longevity of antitumor immune responses induced by B7-transfected tumors. Cancer Res. 54:6477.
39. Freeman, G. J., F. Boriello, R. J. Modes, H. Reiser, J. J. Gribben, J. W. Ng, J. Kim, J. M. Goldberg, K. S. Hathcock, L. A. Lombard, S. Wang, G. S. Gray, et al. 1993. Murine B7-2, an alternative CTLA4 counter-receptor that costimulates T cell proliferation and interleukin-2 production. J. Exp. Med. 178:2185.
40. + T cell immune response to murine myeloid leukemia. Blood 85:2498.
41. Huang, A. Y., P. Golumbek, M. Ahmadzadeh, E. Jaffee, D. Pardoll, and H. Levitsky. 1994. Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens. Science 264:961.
42. Huang, A. Y., A. T. Bruce, D. M. Pardoll, and H. I. Levitsky. 1996. Does B7-1 expression confer antigen-presenting cell capacity to tumors in vivo? J. Exp. Med. 183:769.
43. Yang, G., K. E. Hellstrom, I. Hellstrom, and L. Chen. 1995. Antitumor immunity elicited by tumor cells transfected with B7-2, a second ligand for CD28/CTLA-4 costimulatory molecules. J. Immunol. 154:2794.
44. + T lymphocytes by B7, a natural ligand for CD28, can be used to treat established mouse melanoma. J. Immunol. 153: 421.
45. Ramaralhinam, L., M. Castle, Y. Wu, and Y. Liu. 1994. T cell costimulalion by B7/BB1 induces CD8 T cell-dependent tumor rejection: an important role of B7/BB1 in the induction, recruitment, and effector function of antitumor T cells. J. Exp. Med. 179:1205.
46. Liu, Y., R. H. Wenger, M. Zhao, and P. J. Nielsen. 1997. Distinct costimulatory molecules are required for the induction of effector and memory cytotoxic T lymphocytes. J. Exp. Med. 185:251.
47. Johnston, J. V., A. R. Malacko, M. T. Mizuno, P. Mcgowan, I. Hellstrom, K. E. Hellstrom, H. Marquardt, and L. P. Chen. 1996. B7-CD28 costimulation unveils the hierarchy of tumor epilopes recognized by major histocompatihility complex class I-restricted CD8+ cytotoxic lymphocytes. J. Exp. Med. 183:791.
48. Baskar, S., L. Glimcher, N. Nabavi, R. T. Jones, and S. Ostrand-Rosenberg. 1995. Major histocompatibility complex class II+B7-1+ tumor cells are potent vaccines for stimulating tumor rejection in tumor-bearing mice. J. Exp. Med. 181: 619.
49. Baskar, S., V. K. Clements, L. H. Glimcher, N. Nabavi, and S. Ostrand-Rosenberg. 1996. Rejection of MHC class II-transfected tumor cells requires induction of tumor-encoded B7-1 and/or B7-2 costimulatory molecules. J. Immunol. 156:3821.
50. Nandi, D., J. A. Gross, and J. P. Allison. 1994. CD28-mediated costimulation is necessary for optimal proliferation of murine NK cells. J. Immunol. 152:3361.
51. Chambers, B. J., M. Salcedo, and H. G. Ljunggren. 1996. Triggering of natural killer cells by the costimulatory molecule CD80 (B7-1). Immunity 5:311.
52. Geldhof, A. B., G. Raes, M. Bakkus, S. Devos, K. Thielemans, and P. De Baetselier. 1995. Expression of B7-1 by highly metastatic mouse T lymphomas induces optimal natural killer cell-mediated cytotoxicity. Cancer Res. 55:2730.
53. Yeh, K. Y., B. A. Pulaski, M. L. Woods, A. J. McAdam, A. A. Gaspari, J. C. Frelinger, and E. M. Lord. 1995. B7-1 enhances natural killer cell-mediated cytotoxicity and inhibits tumor growth of a poorly immunogenic murine carcinoma. Cell. Immunol. 165:217.
54. Lenschow, D. J., G. H. Su, L. A. Zuckerman, N. Nabavi, C. L. Jellis, G. S. Gray, J. Miller, and J. A. Bluestone. 1993. Expression and functional significance of an additional ligand for CTLA-4. Proc. Natl. Acad. Sci. USA 90:11054.
55. Hathcock, K. S., G. Laszlo, C. Pucillo, P. Linsley, and R. J. Hodes. 1994. Comparative analysis of B7-1 and B7-2 costimulatory ligands: expression and function. J. Exp. Med. 180:631.
56. Lenschow, D. J., T. L. Walunas, and J. A. Bluestone. 1996. CD28/B7 system of T cell costimulation. Annu. Rev. Immunol. 114:233.
57. Kuchroo, V. K., M. P. Das, J. A. Brown, A. M. Tanger, S. S. Zamvil, R. A. Sobel, H. L. Weiner, N. Nabavi, and L. H. Glimcher. 1995. B7-1 and B7-2 costimulatory molecules activate differentially the Th1/Th2 developmental pathways: application to autoimmune disease. Cell 80:707.
58. Freeman, G. I., V. A. Boussiotis, A. Anumanthan, G. M. Bernstein, X. Y. Ke, P. D. Rennert, G. S. Gray, J. G. Gribben, and L. M. Nadler. 1995. B7-1 and B7-2 do not deliver identical costimulatory signals, since B7-2 but not B7-1 preferentially costimulates the initial production of IL-4. Immunity 2:523.
59. Zitvogel, L. P. D. Robbins, W. J. Storkus, M. R. Clarke, M. J., Maeurer, R. L. Campbell, C. G. Davis, H. Tahara, R. D. Schreiber, and M. T. Lotze. 1996. Interleukin-12 and B7.1 co-stimulation cooperate in the induction of effective antitumor immunity and therapy of established tumors. Eur. J. Immunol 26:1335.
60. Powrie, R. 1995. T cells in inflammatory bowel disease: protective and pathogenic roles. Immunity 3:171.
61. + T cells. Immunity 1:553.